CoChat

The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients

Open access
Sosenko, Jay M., Skyler, Jay S., Palmer, Jerry P., Krischer, Jeffrey P., Yu, Liping, Mahon, Jeffrey, Beam, Craig A., Boulware, David C., Rafkin, Lisa, Schatz, Desmond, Eisenbarth, George, the Type 1 Diabetes TrialNet and the Diabetes Prevention Trial–Type 1 Study Groups · 2013 · Diabetes Care

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: We assessed whether a risk score that incorporates levels of multiple islet autoantibodies could enhance the prediction of type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: TrialNet Natural History Study participants (n = 784) were tested for three autoantibodies (GADA, IA-2A, and mIAA) at their initial screening. Samples from those positive for at least one autoantibody were subsequently tested for ICA and ZnT8A. An autoantibody risk score (ABRS) was developed from a proportional hazards model that combined autoantibody levels from each autoantibody along with their designations of positivity and negativity. RESULTS: The ABRS was strongly predictive of T1D (hazard ratio [with 95% CI] 2.72 [2.23-3.31], P < 0.001). Receiver operating characteristic curve areas (with 95% CI) for the ABRS revealed good predictability (0.84 [0.78-0.90] at 2 years, 0.81 [0.74-0.89] at 3 years, P < 0.001 for both). The composite of levels from the five autoantibodies was predictive of T1D before and after an adjustment for the positivity or negativity of autoantibodies (P < 0.001). The findings were almost identical when ICA was excluded from the risk score model. The combination of the ABRS and the previously validated Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) predicted T1D more accurately (0.93 [0.88-0.98] at 2 years, 0.91 [0.83-0.99] at 3 years) than either the DPTRS or the ABRS alone (P ≤ 0.01 for all comparisons). CONCLUSIONS: These findings show the importance of considering autoantibody levels in assessing the risk of T1D. Moreover, levels of multiple autoantibodies can be incorporated into an ABRS that accurately predicts T1D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc13-0425

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The curves represent 3-year risk estimates according to ABRS categories with (A) and without (B) the inclusion of ICA. Both curves show little overall increment for ABRS values <2.00. For values ≥2.00, the 3-year risk increases with increasing ABRS values in both curves. The number of participants receiving a diagnosis within 3 years of follow-up is shown above each point.
Figure 1 The curves represent 3-year risk estimates according to ABRS categories with (A) and without (B) the inclusion of ICA. Both curves show little overall increment for ABRS values <2.00. For values ≥2.00, the 3-year risk increases with increasing ABRS values in both curves. The number of participants receiving a diagnosis within 3 years of follow-up is shown above each point.CC BY-NC-ND · PubMed Central
Figure 2 The scatterplot shows the association of the ABRS with the DPTRS. The closed circles represent participants diagnosed with T1D. The fractions indicate the number diagnosed over the total in each quadrant. There is a marked predominance of T1D diagnoses among those above both the ABRS and the DPTRS thresholds. The correlation coefficient is shown (Pearson and Spearman coefficients were the same value).
Figure 2 The scatterplot shows the association of the ABRS with the DPTRS. The closed circles represent participants diagnosed with T1D. The fractions indicate the number diagnosed over the total in each quadrant. There is a marked predominance of T1D diagnoses among those above both the ABRS and the DPTRS thresholds. The correlation coefficient is shown (Pearson and Spearman coefficients were the same value).CC BY-NC-ND · PubMed Central
Figure 3 ROC curves at 2 years of follow-up are shown for the ABRS and the combined ABRS and DPTRS. The area under the ROC curve increases from the ABRS to the combined ABRS and DPTRS (P < 0.001 for difference). (The irregularity of the curves reflects statistical estimation variability resulting from the adjustment for censoring.) AUC, area under the curve.
Figure 3 ROC curves at 2 years of follow-up are shown for the ABRS and the combined ABRS and DPTRS. The area under the ROC curve increases from the ABRS to the combined ABRS and DPTRS (P < 0.001 for difference). (The irregularity of the curves reflects statistical estimation variability resulting from the adjustment for censoring.) AUC, area under the curve.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 125

Metadata

Authors
Sosenko, J. M., Skyler, J. S., Palmer, J. P., Krischer, J. P., Yu, L., Mahon, J., Beam, C. A., Boulware, D. C., Rafkin, L., Schatz, D., Eisenbarth, G., & Groups, T. T. 1. D. T. A. T. D. P. T. 1. S.
Affiliations
  • University of Miami (US)
  • University of Washington (US)
  • University of South Florida (US)
  • HLA/DNA Laboratory, Barbara Davis Center for Childhood Diabetes, Denver, Colorado
  • Western University (CA)
  • University of Florida Health (US)
Corresponding author
the Type 1 Diabetes TrialNet and the Diabetes Prevention Trial–Type 1 Study Groups
Venue
Diabetes Care
Published
2013-08-13
Volume
36
Issue
9
Pages
2615-2620
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W1992564715
Cited by
123
References
32
Citations by year
2026: 4 · 2025: 5 · 2024: 11 · 2023: 9 · 2022: 8 · 2021: 10 · 2020: 9 · 2019: 10 · 2018: 4 · 2017: 8 · 2016: 12 · 2015: 12 · 2014: 17 · 2013: 4
FWCI
9.94
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Cambridge University Engineering Department Publications Database (submittedVersion)
Funders
  • American Diabetes Association
  • National Institutes of Health (UL1TR000093, 5ul1rr031986-02, HHSN267200800019C, UL1TR001085, UL1TR000130, UL1TR000005, RR025780, DK017047)
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK-084565, DK017047, U01DK061040, U01DK085461, U01DK085505, 017047, U01DK085499, UL1-RR-024139, U01DK061055, U01DK061036, U01DK061010, U01DK061058, U01DK061034, U01DK061042, U01DK085463, U01DK085453, UC4DK117009, U01DK061041, U01DK085466, UC4DK097835, U01DK085509, U01 DK-061016, P30DK017047)
  • National Institute of Child Health and Human Development
  • U.S. National Library of Medicine (HHSN267200800019C)
  • National Center for Research Resources (UL1RR029890, UL1RR024131, M01RR000400, UL1-RR031986, UL1RR025744, UL1RR024153, UL1RR024982, UL1RR025761, M01-RR00400, UL1RR024975, UL1RR024139, UL1RR025780)
  • National Center for Advancing Translational Sciences
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN267200800019C)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords
type 1 diabetes, islet autoantibodies, disease prediction, GADA, IA-2A, MiaA, Ica, ZnT8A, autoantibody levels
MeSH terms
Adolescent, Adult, Autoantibodies, Child, Child, Preschool, Diabetes Mellitus, Type 1, Female, Humans, Male, Risk Factors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.